Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group

The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically-documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Espanol de Linfoma y Transplante Au...

Descripción completa

Detalles Bibliográficos
Autores: Alonso-Alvarez, S, Magnano, L, Alco-Ceba, M, Andrade-Campos, M, Espinosa-Lara, N, Rodriguez, G, Mercadal, S, Carro, I, Sancho, JM, Moreno, M, Salar, A, Garcia-Pallarols, F, Arranz, R, Cannata, J, Terol, MJ, Teruel, AI, Rodriguez, A, Jimenez-Ubieto, A, de Villambrosia, SG, Bello, JL, Lopez, L, Monsalvo, S, Novelli, S, de Cabo, E, Infante, MS, Pardal, E, Garcia-Alvarez, M, Delgado, J, Gonzalez, M, Martin, A, Lopez-Guillermo, A, Caballero, MD
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p14118
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14118
Access Level:acceso abierto
Palabra clave:transformation
follicular lymphoma
cumulative incidence
id ES_8aaf5a47748a3f42694f6378d5ef445a
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p14118
network_acronym_str ES
network_name_str España
repository_id_str
spelling Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO groupAlonso-Alvarez, SMagnano, LAlco-Ceba, MAndrade-Campos, MEspinosa-Lara, NRodriguez, GMercadal, SCarro, ISancho, JMMoreno, MSalar, AGarcia-Pallarols, FArranz, RCannata, JTerol, MJTeruel, AIRodriguez, AJimenez-Ubieto, Ade Villambrosia, SGBello, JLLopez, LMonsalvo, SNovelli, Sde Cabo, EInfante, MSPardal, EGarcia-Alvarez, MDelgado, JGonzalez, MMartin, ALopez-Guillermo, ACaballero, MDtransformationfollicular lymphomacumulative incidenceThe diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically-documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Espanol de Linfoma y Transplante Autologo de Medula Osea, which recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with FL grades 1-3A, were, (i) the cumulative incidence of HT (CI-HT); (ii) risk factors associated with HT; and (iii) the role of treatment and response on survival following transformation (SFT). With a median follow-up of 6.2 years, 106 patients developed HT. Ten-year CI-HT was 8%. Considering these 106 patients who developed HT, median time to transformation was 2.5 years. High-risk FL International Prognostic Index [Hazard ratio (HR) 2.6, 95% confidence interval (CI): 1.5-4.5] and non-response to first-line therapy (HR 2.9, 95% CI: 1.3-6.8) were associated with HT. Seventy out of the 106 patients died (5-year SFT, 26%). Response to HT first-line therapy (HR 5.3, 95% CI: 2.4-12.0), autologous stem cell transplantation (HR 3.9, 95% CI: 1.5-10.1), and revised International Prognostic Index (HR 2.2, 95% CI: 1.1-4.2) were significantly associated with SFT. Response to treatment and HT were the variables most significantly associated with survival in the rituximab era. Better therapies are needed to improve response. Inclusion of HT in clinical trials with new agents is mandatory.WILEY2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14118BRITISH JOURNAL OF HAEMATOLOGYISSN: 00071048ISSNe: 13652141reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p141182026-06-14T12:41:47Z
dc.title.none.fl_str_mv Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
title Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
spellingShingle Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
Alonso-Alvarez, S
transformation
follicular lymphoma
cumulative incidence
title_short Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
title_full Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
title_fullStr Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
title_full_unstemmed Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
title_sort Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
dc.creator.none.fl_str_mv Alonso-Alvarez, S
Magnano, L
Alco-Ceba, M
Andrade-Campos, M
Espinosa-Lara, N
Rodriguez, G
Mercadal, S
Carro, I
Sancho, JM
Moreno, M
Salar, A
Garcia-Pallarols, F
Arranz, R
Cannata, J
Terol, MJ
Teruel, AI
Rodriguez, A
Jimenez-Ubieto, A
de Villambrosia, SG
Bello, JL
Lopez, L
Monsalvo, S
Novelli, S
de Cabo, E
Infante, MS
Pardal, E
Garcia-Alvarez, M
Delgado, J
Gonzalez, M
Martin, A
Lopez-Guillermo, A
Caballero, MD
author Alonso-Alvarez, S
author_facet Alonso-Alvarez, S
Magnano, L
Alco-Ceba, M
Andrade-Campos, M
Espinosa-Lara, N
Rodriguez, G
Mercadal, S
Carro, I
Sancho, JM
Moreno, M
Salar, A
Garcia-Pallarols, F
Arranz, R
Cannata, J
Terol, MJ
Teruel, AI
Rodriguez, A
Jimenez-Ubieto, A
de Villambrosia, SG
Bello, JL
Lopez, L
Monsalvo, S
Novelli, S
de Cabo, E
Infante, MS
Pardal, E
Garcia-Alvarez, M
Delgado, J
Gonzalez, M
Martin, A
Lopez-Guillermo, A
Caballero, MD
author_role author
author2 Magnano, L
Alco-Ceba, M
Andrade-Campos, M
Espinosa-Lara, N
Rodriguez, G
Mercadal, S
Carro, I
Sancho, JM
Moreno, M
Salar, A
Garcia-Pallarols, F
Arranz, R
Cannata, J
Terol, MJ
Teruel, AI
Rodriguez, A
Jimenez-Ubieto, A
de Villambrosia, SG
Bello, JL
Lopez, L
Monsalvo, S
Novelli, S
de Cabo, E
Infante, MS
Pardal, E
Garcia-Alvarez, M
Delgado, J
Gonzalez, M
Martin, A
Lopez-Guillermo, A
Caballero, MD
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv transformation
follicular lymphoma
cumulative incidence
topic transformation
follicular lymphoma
cumulative incidence
description The diagnostic criteria for follicular lymphoma (FL) transformation vary among the largest series, which commonly exclude histologically-documented transformation (HT) mandatorily. The aims of this retrospective observational multicentre study by the Spanish Grupo Espanol de Linfoma y Transplante Autologo de Medula Osea, which recruited 1734 patients (800 males/934 females; median age 59 years), diagnosed with FL grades 1-3A, were, (i) the cumulative incidence of HT (CI-HT); (ii) risk factors associated with HT; and (iii) the role of treatment and response on survival following transformation (SFT). With a median follow-up of 6.2 years, 106 patients developed HT. Ten-year CI-HT was 8%. Considering these 106 patients who developed HT, median time to transformation was 2.5 years. High-risk FL International Prognostic Index [Hazard ratio (HR) 2.6, 95% confidence interval (CI): 1.5-4.5] and non-response to first-line therapy (HR 2.9, 95% CI: 1.3-6.8) were associated with HT. Seventy out of the 106 patients died (5-year SFT, 26%). Response to HT first-line therapy (HR 5.3, 95% CI: 2.4-12.0), autologous stem cell transplantation (HR 3.9, 95% CI: 1.5-10.1), and revised International Prognostic Index (HR 2.2, 95% CI: 1.1-4.2) were significantly associated with SFT. Response to treatment and HT were the variables most significantly associated with survival in the rituximab era. Better therapies are needed to improve response. Inclusion of HT in clinical trials with new agents is mandatory.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14118
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14118
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv BRITISH JOURNAL OF HAEMATOLOGY
ISSN: 00071048
ISSNe: 13652141
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869412735636209664
score 15,811543

Similares en LA Referencia